Yes. Retatrutide burns fat, and it does it faster and more aggressively than anything else currently in clinical trials. The phase 2 trial published in the New England Journal of Medicine in 2023 showed participants lost up to 24.2% of their body weight over 48 weeks. That number is not a typo.
This is not a stimulant. It is not a thermogenic. It works through a completely different mechanism, and once you understand how it works, the results make sense.
How Does Retatrutide Work to Reduce Body Fat?
Retatrutide is a triple hormone receptor agonist. It activates three receptors at once: GLP-1, GIP, and glucagon. Most people have heard of GLP-1 drugs like semaglutide. Retatrutide does everything semaglutide does, and then adds two more pathways on top of that.
Here is what each receptor does.
- GLP-1 (glucagon-like peptide-1) slows digestion, reduces appetite, and improves insulin sensitivity. This is the same receptor semaglutide targets.
- GIP (glucose-dependent insulinotropic polypeptide) improves how your body handles glucose and works with GLP-1 to amplify the appetite suppression effect. Tirzepatide already uses this combination.
- Glucagon receptor activation is the part that separates retatrutide from everything else. Glucagon tells your liver to burn stored fat for energy. It raises your metabolic rate. It directly drives fat oxidation in a way GLP-1 alone cannot.
In my experience looking at the mechanistic data, the glucagon component is what makes retatrutide different. GLP-1 drugs reduce how much you eat. Glucagon activation changes what your body does with stored fat while you are in that calorie deficit. You get both sides of the equation working at the same time.
Is Retatrutide More Effective Than Semaglutide for Fat Loss?
The data says yes, by a significant margin.
Semaglutide at its highest dose (2.4mg weekly, the Wegovy dose) produces around 15% body weight loss over 68 weeks in the STEP 1 trial. Tirzepatide, which adds GIP to the GLP-1 mechanism, pushed that to around 20-22% in the SURMOUNT-1 trial over 72 weeks.
Retatrutide in the phase 2 trial hit 24.2% at the highest dose over 48 weeks. That is a shorter timeframe and a higher result.
What I found interesting in the data is that the weight loss curve with retatrutide had not plateaued by week 48. Most GLP-1 drugs show a clear flattening of the curve around the 40-week mark. Retatrutide participants were still losing weight at the end of the trial period. That suggests the ceiling may be higher than what the trial captured.
A direct head-to-head trial between retatrutide and semaglutide has not been published yet. But based on the mechanism and the phase 2 numbers, retatrutide produces greater fat loss.
Does Retatrutide Actually Burn Fat or Just Reduce Calories?
Both, and the distinction matters.
GLP-1 drugs primarily work by reducing appetite. You eat less, you lose weight. The fat loss is a downstream effect of the calorie deficit. That is not a criticism, it works, but the mechanism is indirect.
Retatrutide does retatrutide actually burn fat through the glucagon receptor pathway in a more direct way. Glucagon receptor activation increases hepatic fat oxidation, meaning your liver breaks down fat stores for fuel. It also increases energy expenditure, your resting metabolic rate goes up. A 2023 analysis in Nature Metabolism confirmed that glucagon receptor agonism drives thermogenesis and fat mobilisation independent of food intake changes.
So you are getting appetite suppression from GLP-1 and GIP, and you are getting direct fat burning from glucagon. That combination is why the results are larger than GLP-1 drugs alone.
What Are the Side Effects of Retatrutide?
The side effect profile looks similar to other GLP-1 drugs, with nausea being the most common complaint.
In the phase 2 trial, the most reported side effects were:
- Nausea (affecting around 40-50% of participants at higher doses)
- Vomiting
- Diarrhoea
- Constipation
- Decreased appetite (which is also the intended effect)
Most of these were mild to moderate and occurred during the dose escalation phase. When I looked at the dropout rates in the trial, they were comparable to semaglutide trials, which suggests the tolerability is similar.
The glucagon component does raise one specific concern. Glucagon increases heart rate. In the phase 2 trial, participants on the highest dose saw an average heart rate increase of around 5-6 beats per minute. For most healthy people this is not a problem. For people with existing cardiac conditions, it is something to discuss with a doctor before starting.
There is also the standard GLP-1 class warning around pancreatitis and thyroid C-cell tumours, which comes from animal studies. No human cases have been confirmed, but the warning carries over to retatrutide as a class precaution.
Is Retatrutide FDA Approved?
No. As of 2025, retatrutide is not FDA approved.
It completed phase 2 trials in 2023 with strong results. Eli Lilly, the manufacturer, moved it into phase 3 trials. Phase 3 trials are larger, longer, and designed to confirm safety and efficacy across a broader population before a drug can be submitted for approval.
Phase 3 results are expected in 2025-2026. If those results hold up, an FDA submission would follow, and approval could come sometime in 2026 or 2027. That timeline is an estimate based on standard drug development timelines, not a confirmed date.
Retatrutide is not available for prescription anywhere in the world right now through standard medical channels. Anyone selling it currently is selling a research chemical or a compounded version with no regulatory oversight. That carries real risk.
Who Is a Good Candidate for Retatrutide?
Based on the trial inclusion criteria and the mechanism, the strongest candidates are:
- Adults with a BMI of 30 or above
- Adults with a BMI of 27 or above with at least one weight-related health condition like type 2 diabetes, high blood pressure, or sleep apnoea
- People who have not achieved sufficient results with diet and exercise alone
- People who have tried GLP-1 drugs and want a more aggressive option
Retatrutide is not a good fit for people with a personal or family history of medullary thyroid carcinoma, people with multiple endocrine neoplasia syndrome type 2, or people with a history of pancreatitis. The elevated heart rate effect also makes it worth a careful conversation for anyone with existing cardiovascular issues.
What I saw in the trial data is that people with higher starting BMI tended to see the largest absolute weight loss. The drug appears to work harder when there is more metabolic dysfunction to correct. That is consistent with how GLP-1 drugs generally behave.
Can You Use Retatrutide Without Changing Your Diet or Exercise?
The trial participants followed a reduced calorie diet and increased physical activity as part of the protocol. So the 24.2% weight loss number includes lifestyle changes, not the drug alone.
That said, the appetite suppression effect is strong enough that most people naturally eat less without trying to. When I looked at the dietary adherence data from similar GLP-1 trials, participants consistently reported that following a calorie deficit felt easier on the drug than off it. The drug changes the hunger signal, so the behaviour change becomes less effortful.
But the people who combine the drug with structured nutrition and training get better results. That is true for every weight loss intervention ever studied. The drug is a tool, not a replacement for the fundamentals.
If you are using or planning to use a drug like retatrutide, working with a coach who understands body composition, not just weight loss, will produce better outcomes. Losing 24% of your body weight without a plan to preserve muscle means you lose a significant amount of lean mass along with the fat. That matters for long-term metabolic health.
FAQ
Does retatrutide work for people without diabetes?
Yes. The phase 2 trial included people with and without type 2 diabetes. Both groups lost significant weight. The drug is being developed as an obesity treatment, not just a diabetes drug.
How is retatrutide different from tirzepatide?
Tirzepatide targets GLP-1 and GIP. Retatrutide adds glucagon receptor activation on top of those two. That third receptor is what drives the additional fat oxidation and the higher weight loss numbers.
How long do you need to take retatrutide?
Based on what we know from GLP-1 drugs, weight tends to return when the drug is stopped. Retatrutide will likely follow the same pattern. The STEP 1 extension trial for semaglutide showed participants regained most of their weight within a year of stopping. Retatrutide is probably a long-term or indefinite treatment for most people, not a short course.
Will retatrutide be available in Australia?
Once FDA approved, it would go through the TGA approval process in Australia separately. That typically adds 12-24 months after US approval. Realistically, Australian availability through standard prescription channels is probably 2027-2028 at the earliest.
Is retatrutide safe long-term?
We do not have long-term safety data yet. Phase 2 trials run for under a year. Phase 3 trials will provide more data. The GLP-1 drug class has a reasonable long-term safety record based on semaglutide and liraglutide data going back over a decade, but retatrutide’s glucagon component adds a variable that needs longer observation.
Can exercise replace retatrutide?
Exercise and retatrutide work through completely different mechanisms. Exercise builds muscle, improves insulin sensitivity, and burns calories. Retatrutide suppresses appetite and drives fat oxidation through hormone receptor pathways. They are not substitutes for each other. The best outcomes come from combining both.
